Looking to expand your partner network with leading companies like Apitope? Consider joining Inpart's global network for free.
More News! 16 Apr 2018
Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases
The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves’ disease, one of the most common autoimmune diseases. Apitope has obtained positive clinical results indicating its treatment for Graves’ disease is safe and well-tolerated. A common autoimmune disease affecting the thyroid, Graves’ disease occurs when a patient’s immune system […]